Viatris Inc.
$32.48B- Market cap
- $19.39B
- Debt
- +$14.41B
- Cash
- −$1.32B
Capital structure 57% equity / 43% debt · EV / Revenue 2.27x · EV / EBITDA 1393.83x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $19.39B · View financials
Snapshot Sep 4, 4:00 PM ET
Decision snapshot: VTRS stock price at discount vs HRMY $16.88 current versus $35.27 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at HRMY's multiple
Implied fair value · at VTRS's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: VTRS FY 2025 (ended Dec 31, 2025) · HRMY FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 57% equity / 43% debt · EV / Revenue 2.27x · EV / EBITDA 1393.83x
Capital structure 94% equity / 6% debt · EV / Revenue 2.13x · EV / EBITDA 7.27x
VTRS carries the larger enterprise value at $32.48B against $1.85B; HRMY trades on the lower EV / Revenue multiple (2.13x vs 2.27x); HRMY on the lower EV / EBITDA (7.27x vs 1393.83x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
VIATRIS INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
HARMONY BIOSCIENCES HOLDINGS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.98x
0.19x
Net debt / EBITDA
Leverage against operating earnings
561.72x
-2.41x
Cash and equivalents
Liquid reserves on the balance sheet
$1.32B
$775.34M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
VTRS vs PFE
Organon & Co.
VTRS vs OGN
BRISTOL MYERS SQUIBB CO
VTRS vs BMY
AbbVie Inc.
VTRS vs ABBV
Merck & Co., Inc.
VTRS vs MRK
Jazz Pharmaceuticals plc
VTRS vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
VTRS vs SUPN
Intra-Cellular Therapies, Inc.
VTRS vs ITCI
ACADIA PHARMACEUTICALS INC
VTRS vs ACAD
Vanda Pharmaceuticals Inc.
VTRS vs VNDA
LivaNova PLC
VTRS vs LIVN
$14.41B
$163.66M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.